Fidia S.p.A. (BIT:FDA)
Italy · Delayed Price · Currency is EUR | Market Cap | 3.43M |
| Revenue (ttm) | 21.13M |
| Net Income (ttm) | -2.19M |
| Shares Out | 14.90M |
| EPS (ttm) | -1.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 109,785 |
| Average Volume | 248,243 |
| Open | 0.2358 |
| Previous Close | 0.2360 |
| Day's Range | 0.2224 - 0.2358 |
| 52-Week Range | 0.2000 - 10.4000 |
| Beta | 0.02 |
| RSI | 43.66 |
| Earnings Date | Nov 14, 2025 |
About Fidia
Fidia S.p.A., together with its subsidiaries, designs, manufactures, and sells high speed milling systems, numerical controls, milling heads, and software systems. Its accessories comprise HMS, a device for measuring and compensating geometric error on continuous or indexed bi-rotary heads and roto-tilting tables; TMSC, a device to measure length and diameter of the tool, as well as to check the shape; K5 tracer, a solution to perform continuous scanning of 3D surfaces; pushbutton panels; XPower digital drives for axis and spindle movement; and... [Read more]
Financial Performance
In 2024, Fidia's revenue was 17.53 million, a decrease of -38.98% compared to the previous year's 28.74 million. Losses were -9.30 million, 611.4% more than in 2023.
Financial StatementsNews
Biotech Stocks Facing FDA Decision In November 2025
(RTTNews) - November, a month best known for Thanksgiving and harvest festivals, is also an important month for raising awareness about various health issues. Some of the key health observances in Nov...
Johnson & Johnson (JNJ) Seeks FDA Approval for Expanded Use of Stelara
Johnson & Johnson (JNJ) Seeks FDA Approval for Expanded Use of Stelara
J&J submits application to FDA for expanded use of Stelara
Implantica AG (FRA:8IM1) Q3 2025 Earnings Call Highlights: Navigating FDA Approvals and ...
Implantica AG (FRA:8IM1) Q3 2025 Earnings Call Highlights: Navigating FDA Approvals and Strategic Growth
FDA cracks down on fluoride supplements for children
The Food and Drug Administration (FDA) has put four companies on notice for marketing “unapproved fluoride-containing ingestible drugs” for use by children under the age of 3 or children at low or mod...
Hong Thai owner slams FDA for raids
The owner of Hong Thai herbal inhalants has called on the Food and Drug Administration (FDA) to adopt a more constructive regulatory approach, urging the agency to support product development rather t...
CRISPR Therapeutics (CRSP) Gains as FDA Eases Approval Pathway
CRISPR Therapeutics (CRSP) Gains as FDA Eases Approval Pathway
Gene editing therapy companies rise on word of streamlined FDA approval process
The FDA intends to make it easier for gene editing therapies to gain approval. Read more here.
FDA to Expedite Gene-Editing Approval Process, Impacting CRSP
FDA to Expedite Gene-Editing Approval Process, Impacting CRSP
FDA clears way for faster personalized gene editing therapy
Health Secretary Robert F. Kennedy Jr. called the treatment 'a powerful glimpse into the future of personalized medicine'
NVNO: Financial Stability as FDA Discussions Progress
NVNO: Financial Stability as FDA Discussions Progress
Police raid illegal herbal inhaler factories, seize over 2m items worth over B100m
Consumer Protection Police Division (CPPD) officers and Food and Drug Administration (FDA) personnel have raided four unlicensed herbal inhaler factories producing the popular “Hong Thai” brand and se...
Travere signals readiness for rapid FILSPARI launch in FSGS as Q3 2025 revenue hits $164.9M
Discover key Q3 2025 earnings insights for Travere Therapeutics, including FILSPARI sales growth, FDA milestones, and outlook for rare kidney disease...
Lantheus (LNTH) Awaits FDA Decision on Diagnostic Kit
Lantheus (LNTH) Awaits FDA Decision on Diagnostic Kit
Global Surgical Instrument Tracking Systems Market to Reach USD 751.2 Million by 2030 | MarketsandMarkets™
Delray Beach, FL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The global surgical instrument tracking systems market , valued at US$314.2 million in 2024, stood at US$371.4 million in 2025 and is projected to a...
Republican senators blast FDA for expanding abortion pill access
Senators cite study showing 22 times higher serious side effects from chemical abortion drugs than FDA labels indicate, calling for safety guardrail restoration.
Lantheus Gets FDA PDUFA Date For LNTH-2501 Diagnostic Kit In March
(RTTNews) - Lantheus Holdings, Inc. (LNTH) said Thursday that the U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of March 29, 2026, for LNT...
FDA Commissioner Dr. Marty Makary on streamlining approvals for biosimilar generic drugs
FDA Commissioner Dr. Marty Makary joins 'Squawk Box' to discuss plans to speed up the approval of biosimilar generic drugs in a plan to help lower health care costs, pushback from the pharmaceuticals ...
FDA Streamlines Biosimilar Development; Impacts AstraZeneca (AZN)
FDA Streamlines Biosimilar Development; Impacts AstraZeneca (AZN)
Biocon shares rise nearly 2% after US FDA moves to ease biosimilar approvals, boosting outlook for Indian biopharma exporters
Biocon shares gained on Thursday, October 30, rising nearly 2% to Rs 380 amid positive sentiment in the biopharmaceutical sector...
Intellia Therapeutics (NTLA) Faces FDA Hold After Severe Adverse Event in Nex-Z Trial
Intellia Therapeutics (NTLA) Faces FDA Hold After Severe Adverse Event in Nex-Z Trial
Amneal Pharmaceuticals (AMRX) Receives Tentative FDA Approval for Generic Inhaler
Amneal Pharmaceuticals (AMRX) Receives Tentative FDA Approval for Generic Inhaler
FDA Streamlines Biosimilar Approval Process, Impacting AMGN
FDA Streamlines Biosimilar Approval Process, Impacting AMGN
Intellia drops after market close on FDA clinical hold on nex-z trials
The FDA has halted Intellia Therapeutics’ phase 3 trials for nex-z after a severe liver-related adverse event in a patient. Read more here.